Active ingredients
Pharmacological Group
Used in the treatment of
- T43.3 Poisoning, phenothiazine antipsychotics and neuroleptics
- T42.4 Poisoning, benzodiazepines
- R53 Malaise and fatigue
- R46.4 Slowness and poor responsiveness
- R45.3 Demoralization and apathy
- R40.1 Stupor
- F79 Unspecified mental retardation
- F51.1 Nonorganic hypersomnia
- F48.9 Neurotic disorder, unspecified
- F48.0 Neurasthenia
- F20.9 Schizophrenia, unspecified
- F10.2 Mental and behavioural disorders due to use of alcohol, dependence syndrome
- F10.3 Mental and behavioural disorders due to use of alcohol, withdrawal state
- F10 Mental and behavioural disorders due to use of alcohol
- F06.6 Organic emotionally labile [asthenic] disorder
- T65 Toxic effect of other and unspecified substances
- T90.5 Sequelae of intracranial injury
- Y47.1 Adverse effects in therapeutic use, benzodiazepines
- Y49.3 Adverse effects in therapeutic use, phenothiazine antipsychotics and neuroleptics
- Y49.4 Adverse effects in therapeutic use, butyrophenone and thioxanthene neuroleptics
- Y49.5 Adverse effects in therapeutic use, other antipsychotics and neuroleptics
- Z73.0 Burn-out
- Z73.6 Limitation of activities due to disability